Soluble programmed death ligand 1 as prognostic biomarker in non-small cell lung cancer patients receiving nivolumab, pembrolizumab or atezolizumab therapy

Nature·Apr 18

✦ NabkaNews BriefAuto-summarized from multiple outlets · verify with the source

Research is being conducted on the role of soluble programmed death ligand 1 as a prognostic biomarker in non-small cell lung cancer patients receiving certain therapies. The focus of this specific study appears to be on patients treated with nivolumab, pembrolizumab, or atezolizumab. However, other studies are also exploring the prognostic value of soluble programmed death ligand 1 in various other diseases and conditions, including different types of cancer and traumatic brain injury.

Full coverage

Serum programmed death ligand 2 is elevated in cats with mammary carcinoma | Scientific Reports

Nature·Feb 24

Targeting PD-L1 for PCNS-DLBCL: from molecular effects to clinical translation

Frontiers·Sep 11

Association between B and T lymphocyte attenuator/herpes virus entry mediator immunoregulatory axis and outcome prediction in a mixed critically ill population

Nature·Mar 13

Biological Characteristics and Clinical Significance of Soluble PD-1/PD-L1 and Exosomal PD-L1 in Cancer

Frontiers·Feb 11

Programmed Cell Death-Ligand-1 expression in Bladder Schistosomal Squamous Cell Carcinoma – There’s room for Immune Checkpoint Blockage?

Frontiers·Feb 9

Prognostic value of soluble programmed death-1 and soluble programmed death ligand-1 in severe traumatic brain injury patients

Nature·Oct 11

Soluble biomarkers to predict clinical outcomes in non-small cell lung cancer treated by immune checkpoints inhibitors

Frontiers·Feb 8

Soluble programmed death-ligand 1 rather than PD-L1 on tumor cells effectively predicts metastasis and prognosis in soft tissue sarcomas

Nature·Jun 3

View original report at Nature ↗

Fetching the latest headlines…